secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001683168-24-003063
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance
--------------------------------------------------------------------------------

- Hearing held April 18, 2024; panel grants extension until July 15, 2024.
- Must demonstrate compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)).
- Company intends to implement its plan to meet the milestones set by the Panel.
- Failure to comply by July 15 could result in delisting from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/0001683168-24-003063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer